Long-term studies with xamoterol in heart failure

Area of Science:

• Pharmacology
• Cardiology
• Internal Medicine

Background:

• Xamoterol is a selective beta 1-adrenoceptor partial agonist.
• Unlike full agonists, it does not cause beta-adrenoceptor down-regulation in rat ventricles during chronic administration.

Purpose of the Study:

• To evaluate the efficacy and safety of xamoterol in patients with mild to moderate heart failure.
• To assess the long-term effects of xamoterol on myocardial performance, exercise duration, and mortality.

Main Methods:

• Clinical studies involving patients with mild or moderate heart failure and left ventricular dysfunction.
• Assessment of myocardial performance, exercise duration, adverse events, and mortality over extended treatment periods (up to 1 year).

Main Results:

• Acute xamoterol administration improved myocardial performance, with sustained benefits over 1 year.
• Increased exercise duration was observed in patients with left ventricular dysfunction, persisting after 1 year.
• No adverse effect on mortality was noted despite sustained cardiac stimulation.
• Few drug-related adverse events and a good laboratory safety profile were reported over 1 year.

Conclusions:

• Xamoterol demonstrates sustained efficacy in improving cardiac function and exercise capacity in heart failure.
• It is a well-tolerated treatment option with a favorable safety profile for chronic heart failure management.
• Xamoterol represents a promising addition to existing therapies for mild to moderate heart failure.